616 related articles for article (PubMed ID: 15921374)
1. The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.
La Starza R; Specchia G; Cuneo A; Beacci D; Nozzoli C; Luciano L; Aventin A; Sambani C; Testoni N; Foppoli M; Invernizzi R; Marynen P; Martelli MF; Mecucci C
Haematologica; 2005 May; 90(5):596-601. PubMed ID: 15921374
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.
Vandenberghe P; Wlodarska I; Michaux L; Zachée P; Boogaerts M; Vanstraelen D; Herregods MC; Van Hoof A; Selleslag D; Roufosse F; Maerevoet M; Verhoef G; Cools J; Gilliland DG; Hagemeijer A; Marynen P
Leukemia; 2004 Apr; 18(4):734-42. PubMed ID: 14973504
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.
Helbig G; Moskwa A; Hus M; Piszcz J; Swiderska A; Urbanowicz A; Całbecka M; Gajkowska J; Seferyńska I; Hałasz M; Woszczyk D; Markiewicz M; Krzemień S
Hematol Oncol; 2010 Jun; 28(2):93-7. PubMed ID: 19728396
[TBL] [Abstract][Full Text] [Related]
4. FIP1L1-PDGFRalpha alone or with other genetic abnormalities reveals disease progression in chronic eosinophilic leukemia but good response to imatinib.
Wang LN; Pan Q; Fu JF; Shi JY; Jin J; Li JM; Hu J; Zhao WL; Chen Z; Chen SJ
Chin Med J (Engl); 2008 May; 121(10):867-73. PubMed ID: 18706197
[TBL] [Abstract][Full Text] [Related]
5. [Characteristics of cytogenetics and molecular biology in patients with eosinophilia].
Qu SQ; Ai XF; Li CW; Li QH; Xu ZF; Qin TJ; Zhang Y; Xiao ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1216-20. PubMed ID: 23114151
[TBL] [Abstract][Full Text] [Related]
6. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.
Pardanani A; Ketterling RP; Brockman SR; Flynn HC; Paternoster SF; Shearer BM; Reeder TL; Li CY; Cross NC; Cools J; Gilliland DG; Dewald GW; Tefferi A
Blood; 2003 Nov; 102(9):3093-6. PubMed ID: 12842979
[TBL] [Abstract][Full Text] [Related]
7. FIP1L1-PDGFRA in chronic eosinophilic leukemia and BCR-ABL1 in chronic myeloid leukemia affect different leukemic cells.
Crescenzi B; Chase A; Starza RL; Beacci D; Rosti V; Gallì A; Specchia G; Martelli MF; Vandenberghe P; Cools J; Jones AV; Cross NC; Marynen P; Mecucci C
Leukemia; 2007 Mar; 21(3):397-402. PubMed ID: 17215855
[TBL] [Abstract][Full Text] [Related]
8. A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Salemi S; Yousefi S; Simon D; Schmid I; Moretti L; Scapozza L; Simon HU
Allergy; 2009 Jun; 64(6):913-8. PubMed ID: 19210352
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.
Metzgeroth G; Walz C; Erben P; Popp H; Schmitt-Graeff A; Haferlach C; Fabarius A; Schnittger S; Grimwade D; Cross NC; Hehlmann R; Hochhaus A; Reiter A
Br J Haematol; 2008 Dec; 143(5):707-15. PubMed ID: 18950453
[TBL] [Abstract][Full Text] [Related]
10. A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.
Helbig G; Stella-Hołowiecka B; Majewski M; Całbecka M; Gajkowska J; Klimkiewicz R; Moskwa A; Grzegorczyk J; Lewandowska M; Hołowiecki J
Br J Haematol; 2008 Apr; 141(2):200-4. PubMed ID: 18307562
[TBL] [Abstract][Full Text] [Related]
11. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management.
Gotlib J; Cools J; Malone JM; Schrier SL; Gilliland DG; Coutré SE
Blood; 2004 Apr; 103(8):2879-91. PubMed ID: 15070659
[TBL] [Abstract][Full Text] [Related]
12. [The activation of JAK/STAT signal pathway in hypereosinophilic syndrome and the patients therapeutic response to imatinib].
Li B; Zhang GS; Dai CW; Pei MF
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):448-52. PubMed ID: 15854548
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study.
Baccarani M; Cilloni D; Rondoni M; Ottaviani E; Messa F; Merante S; Tiribelli M; Buccisano F; Testoni N; Gottardi E; de Vivo A; Giugliano E; Iacobucci I; Paolini S; Soverini S; Rosti G; Rancati F; Astolfi C; Pane F; Saglio G; Martinelli G
Haematologica; 2007 Sep; 92(9):1173-9. PubMed ID: 17666373
[TBL] [Abstract][Full Text] [Related]
14. A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint.
Lambert F; Heimann P; Herens C; Chariot A; Bours V
J Mol Diagn; 2007 Jul; 9(3):414-9. PubMed ID: 17591942
[TBL] [Abstract][Full Text] [Related]
15. Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Arai A; Yan W; Wakabayashi S; Hayashi S; Inazawa J; Miura O
Int J Hematol; 2007 Oct; 86(3):233-7. PubMed ID: 17988989
[TBL] [Abstract][Full Text] [Related]
16. Response to imatinib mesylate in patients with hypereosinophilic syndrome.
Arefi M; García JL; Briz MM; de Arriba F; Rodríguez JN; Martín-Núñez G; Martínez J; López J; Suárez JG; Moreno MJ; Merino MA; Gutiérrez NC; Hernández-Rivas JM
Int J Hematol; 2012 Sep; 96(3):320-6. PubMed ID: 22806436
[TBL] [Abstract][Full Text] [Related]
17. Detection of FIP1L1-PDGFRA fusion by FISH.
Ma ES; Wong KF; Wong CL; Siu LL
Br J Haematol; 2007 Aug; 138(3):279. PubMed ID: 17542982
[No Abstract] [Full Text] [Related]
18. Imatinib mesylate as a novel treatment option for hypereosinophilic syndrome: two case reports and a comprehensive review of the literature.
Müller AM; Martens UM; Hofmann SC; Bruckner-Tuderman L; Mertelsmann R; Lübbert M
Ann Hematol; 2006 Jan; 85(1):1-16. PubMed ID: 16136348
[TBL] [Abstract][Full Text] [Related]
19. FIP1L1-PDGFRA positive chronic eosinophilic leukaemia and associated central nervous system involvement.
Williams C; Kalra S; Nath U; Bown N; Wilson V; Wilkins BS; Neylon AJ
J Clin Pathol; 2008 May; 61(5):677-80. PubMed ID: 18256119
[TBL] [Abstract][Full Text] [Related]
20. FIP1L1-PDGFR alpha, a therapeutic target for the treatment of chronic eosinophilic leukemia.
Cools J
Verh K Acad Geneeskd Belg; 2005; 67(3):169-76. PubMed ID: 16089297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]